Caris Life Sciences' Q3 revenue rises on molecular profiling strength
Overview
US molecular diagnostics firm's Q3 revenue rose 27% yr/yr, driven by molecular profiling growth
Net income fell yr/yr as operating expenses rose on headcount, R&D and marketing costs
Company raised 2026 revenue guidance to $1.04-$1.05 bln, up 28-29% yr/yr
Outlook
Caris Life Sciences expects 2026 revenue guidance of $1.04-$1.05 bln
Company reaffirms 2026 clinical therapy selection volume growth of about 20%
Result Drivers
MOLECULAR PROFILING GROWTH - Co said revenue growth was primarily driven by a 27% increase in molecular profiling services, attributed to higher clinical case volume and improved average selling prices
CLINICAL CASE VOLUME - Co completed approximately 61,500 clinical cases in Q3, up 21% yr/yr, supporting revenue growth
OPERATING EXPENSES - Higher headcount, R&D investment, and marketing spending contributed to a 42% rise in operating expenses
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | $275.36 mln | ||
Q3 Net Income | $15.25 mln | ||
Q3 Income From Operations | $19.32 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Caris Life Sciences, Inc. is $30.00, about 8.7% below its November 3 closing price of $32.85
The stock recently traded at 94 times the next 12-month earnings vs. a P/E of 65 three months ago
Reuters Recommended Reads
Nov 4 - Charles River Laboratories Q3 revenue beats estimates, lifts 2026 outlook
Nov 3 - Stevanato Group Q3 revenue beats estimates on biopharma segment
Nov 3 - SOPHiA GENETICS Q3 revenue rises on US market strength
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)